Lilly’s Ultra Rapid Lispro Mealtime Insulin Sails Through Phase III, But Will It Be Enough?
Executive Summary
With only slight potential advantages in some types of patients, ultra-rapid insulins will likely still need to compete on price to be more widely successful, analysts say.
You may also be interested in...
Keeping Track: Keytruda Claims First TMB-Based Cancer Indication; TG Therapeutics Submits First Umbralisib NDA
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Keeping Track Of Non-Oncology Review and Approval News: Erectile Dysfunction, Parkinson's, Cholesterol
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
FDA's NDA And BLA Approvals: Fiasp, Ascor
Original new drugs and biologics approved by US FDA.